| Programs | Development | Regulatory Submission | Regulatory Approval | Current Status | |
|---|---|---|---|---|---|
| Enbumyst™ (bumetanide nasal spray) 0.5 mg | |||||
FDA Approval | 
FDA Approval | ||||
| RSQ-786 | Subcutaneous Diuretic (Multidose Pen Injector) | |||||
Development | |||||
| RSQ-789 | Subcutaneous Diuretic (Smart Infusion System) | |||||
Development | |||||
| RSQ-781 | Veterinary Diuretic Spray | |||||
Development | |||||
| Programs | ||
|---|---|---|
| Development | Regulatory Submission | Regulatory Approval |
| Enbumyst™ (bumetanide nasal spray) 0.5 mg | | ||
| RSQ-786 | Subcutaneous Diuretic (Multidose Pen Injector) | ||
| RSQ-789 | Subcutaneous Diuretic (Smart Infusion System) | ||
| RSQ-781 | Veterinary Diuretic Spray | ||
Enbumyst has received regulatory approval. Corstasis Therapeutics’ other pipeline products remain investigational and have not been approved by regulatory authorities, including the U.S. Food and Drug Administration (FDA) or equivalent global agencies. The safety, efficacy, and clinical use of these investigational therapies have not been established. All information provided is for educational and informational purposes only and should not be construed as medical advice or a recommendation for use. For questions about medical conditions or treatment options, please consult a qualified healthcare professional.